<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62224</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Diagnostic value of cardiac 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy in Lewy body disorders</dc:title>
<dc:description xml:lang="en">Introduction. Lewy body disorders such as Parkinson&#146;s disease(PD) and Lewy body dementia (LBD) are associated withcardiac sympathetic denervation, which can be visualized on123I-MIBG scintigraphy. Our objectives were to study the diagnosticvalue of this technique in Lewy body disorders and its relationshipwith PD clinical variables.Patients and methods. We studied 90 patients: 51 with PD,19 with LBD, 9 with multiple system atrophy (MSA) and 11 controls.Scintigraphy images were qualitatively evaluated and earlyand delayed heart-to-mediastinum ratios (HMR) were calculated.The main confounding factors (ischemic heart disease, diabetes,hypertension and drugs) were controlled by multivariate linearregression analysis. We investigated correlations between scintigraphyvariables and PD variables.Results. The delayed HMR, which showed better discriminativeability was 2.03 ± 0.32 in controls, 1.37 ± 0.30 in PD(p&lt;0.001 vs controls), 1.47±0.45 in LBD (p=0.001 vs controls) and1.69±0.28 in MSA (p=0.02 vs controls; p=0.004 vs PD). This ratiowas influenced by PD/LBD diagnosis (ß=&#150;0.638; p&lt;0.001)and to a lesser degree, by ischemic heart disease (ß = &#150;0.244;p=0.028). Optimal cut-off value between PD/LBD and controlswas 1.71 (83% sensitivity and 82% specificity). Within the PDgroup, those with a family history of PD/LB showed higher delayedHMR values (1.65±0.34 vs 1.30±0.24 without history; p&lt;0.001)and proportion with normal scintigraphy (56% vs 5%; p=0.001).Conclusions. Cardiac 123I-MIBG scintigraphy is useful in thediagnosis of Lewy body disorders, although its value in PD isconditioned by having a family history of PD (AU)</dc:description>
<dc:creator>Rebollo-Aguirre, A. C</dc:creator>
<dc:creator>Ortega-León, T</dc:creator>
<dc:creator>Ortega-Moreno, A</dc:creator>
<dc:creator>Gallego-Peinado, M</dc:creator>
<dc:creator>Muñoz-Pasadas, M</dc:creator>
<dc:creator>Mínguez-Castellanos, A</dc:creator>
<dc:creator>Escamilla-Sevilla, F</dc:creator>
<dc:creator>Pérez-Navarro, M. J</dc:creator>
<dc:creator>Carnero-Pardo, C</dc:creator>
<dc:creator>Cabello-García, D</dc:creator>
<dc:creator>Gómez-Río, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. Enfermedades con cuerpos de Lewy (ECL), como laenfermedad de Parkinson (EP) y la demencia con cuerpos de Lewy(DCL), asocian una denervación simpática cardíaca que puede evidenciarsemediante gammagrafía con 123I-metaiodobenzilguanidina(123I-MIBG). Nuestros objetivos fueron estudiar su valor diagnósticoen las ECL y su relación con variables clínicas de la EP.Pacientes y métodos. Estudiamos 90 pacientes: 51 con EP, 19 conDCL, 9 con atrofia multisistémica (AMS) y 11 controles. Se realizó valoracióncualitativa de la gammagrafía y se calcularon los índices corazón/mediastino (ICM) precoz y tardío. Los principales factores deconfusión (cardiopatía isquémica, diabetes, hipertensión y fármacos)se controlaron mediante regresión lineal multivariante. Efectuamoscorrelaciones entre las variables gammagráficas y del grupo con EP.Resultados. El ICM tardío, con mayor capacidad discriminativa,fue 2,03±0,32 en los controles, 1,37±0,30 en EP (p&lt;0,001 vs controles),1,47±0,45 en DCL (p=0,001 vs controles) y 1,69±0,28 enAMS (p=0,02 vs controles; p=0,004 vs EP). En este índice influía eldiagnóstico de ECL (ß=&#150;0,638; p&lt;0,001) y en menor grado la cardiopatíaisquémica (ß=&#150;0,244; p=0,028). Identificamos el valor 1,71como mejor punto de corte entre ECL y controles (sensibilidad 83%y especificidad 82%). Dentro del grupo con EP, aquellos con antecedentesfamiliares de EP mostraron mayores ICM tardío (1,65±0,34 vs1,30±0,24 sin antecedentes; p&lt;0,001) y proporción de gammagrafíasnormales (56% vs 5%; p=0,001).Conclusiones. La gammagrafía cardíaca con 123I-MIBG es útilen el diagnóstico de ECL, si bien, en la EP su valor está condicionadopor el hecho de tener historia familiar de la enfermedad (AU)</dc:description>
<dc:source>Neurologia;24(3): 170-176, abr. 2009. graf, tab</dc:source>
<dc:identifier>ibc-62224</dc:identifier>
<dc:title xml:lang="es">Valor diagnóstico de la gammagrafíacardíaca con 123I-metaiodobenzilguanidinaen las enfermedades con cuerpos de Lewy</dc:title>
<dc:subject>^d34224^s22053</dc:subject>
<dc:subject>^d34224^s22032</dc:subject>
<dc:subject>^d6473^s22037</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d10489^s22032</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d10489^s22053</dc:subject>
<dc:subject>^d33090</dc:subject>
<dc:subject>^d10489^s22008</dc:subject>
<dc:subject>^d13942</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d34224^s22016</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:type>article</dc:type>
<dc:date>200904</dc:date>
</metadata>
</record>
</ibecs-document>
